Loading clinical trials...
Loading clinical trials...
A Late Phase Randomized Open-Label Multi Cohort Trial to Evaluate irAEs With Different Standard of Care Dosing Strategies of Standard of Care Immunotherapies
Conditions
Interventions
Nivolumab
Pembrolizumab
Locations
1
United States
The University of Kansas Cancer Center
Westwood, Kansas, United States
Start Date
October 7, 2025
Primary Completion Date
October 1, 2027
Completion Date
October 1, 2029
Last Updated
December 8, 2025
NCT07486713
NCT07476781
NCT06927297
NCT07181473
NCT07299747
NCT07128914
Lead Sponsor
University of Kansas Medical Center
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions